News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
